Dashboard
Manage Tickers

FOLD AMICUS THERAPEUTICS, INC.

Nasdaq amicusrx.com


$ 9.01 $ 0.13 (1.47 %)    

Tuesday, 04-Nov-2025 15:59:59 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 615.11 $ -4.04 (-0.65 %)
DIA $ 470.25 $ 0.57 (0.12 %)
SPY $ 672.36 $ -0.79 (-0.12 %)
TLT $ 90.13 $ 0.15 (0.17 %)
GLD $ 362.19 $ -1.27 (-0.35 %)
$ 8.99
$ 9.08
$ 8.69 x 1
$ 9.70 x 30
$ 8.85 - $ 9.64
$ 5.51 - $ 12.65
9,726,906
na
2.77B
$ 0.80
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 07-31-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-19-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-01-2023 12-31-2022 10-K
13 11-07-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-02-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-05-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 03-01-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-09-2017 03-31-2017 10-Q
36 03-01-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-03-2016 03-31-2016 10-Q
40 02-29-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

amicus-2025-outlook-reiterates-financial-guidance-with-revenue-growth-target-of-15-to-22-reflecting-continued-business-expansion
Amicus 2025 Outlook Reiterates Financial G...
11/04/2025 12:04:18

2025 Financial GuidanceAmicus reiterates its financial guidance for 2025, as follows:Total Revenue Growth115% to 22%Galafold Re...

amicus-therapeutics-q3-adj-eps-017-beats-004-estimate-sales-169061m-beat-165706m-estimate
Amicus Therapeutics Q3 Adj. EPS $0.17 Beat...
11/04/2025 12:02:43

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

this-csx-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday
This CSX Analyst Turns Bullish; Here Are T...
09/18/2025 11:23:26

needham-upgrades-amicus-therapeutics-to-buy-announces-14-price-target
Needham Upgrades Amicus Therapeutics to Bu...
09/18/2025 10:00:55

Needham analyst Gil Blum upgrades Amicus Therapeutics (NASDAQ:FOLD) from Hold to Buy and announces $14 price target.

amicus-therapeutics-reports-4-year-muscle-function-and-biomarker-data-from-propel-study-of-cipaglucosidase-alfa--miglustat-in-late-onset-pompe-disease
Amicus Therapeutics Reports 4-Year Muscle ...
09/08/2025 13:05:49

Amicus Therapeutics (NASDAQ:FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarke...

amicus-therapeutics-affirms-fy2025-sales-guidance-of-607539m-644520m-vs-620675m-est
Amicus Therapeutics Affirms FY2025 Sales G...
07/31/2025 11:14:20

2025 Financial GuidanceAmicus reiterates its financial guidance for 2025, as follows:Total Revenue Growth115% to 22% Galafold R...

amicus-therapeutics-q2-adj-eps-001-beats-011-estimate-sales-154688m-beat-147399m-estimate
Amicus Therapeutics Q2 Adj. EPS $0.01 Beat...
07/31/2025 11:06:47

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $...

Core News & Articles
Earnings Scheduled For July 31, 2025
07/31/2025 08:32:50

morgan-stanley-upgrades-amicus-therapeutics-to-overweight-raises-price-target-to-108
Morgan Stanley Upgrades Amicus Therapeutic...
07/17/2025 11:33:37

Morgan Stanley analyst Jeffrey Hung upgrades Amicus Therapeutics (NASDAQ:FOLD) from Equal-Weight to Overweight and raises th...

amicus-therapeutics-receives-approval-from-japans-ministry-of-health-labour-and-welfare-for-pombiliti--opfolda
Amicus Therapeutics Receives Approval From...
06/25/2025 11:05:29

amicus-therapeutics-announced-the-publication-of-a-post-hoc-analysis-of-data-from-the-ert-experienced-cohort-of-the-propel-study-of-cipaglucosidase-alfa-atga--miglustat-cipamig-in-adults-with-late-onset-pompe-disease-in-muscle-and-nerve
Amicus Therapeutics Announced The Publicat...
06/03/2025 11:13:06

PROPEL was a 52-week, double-blind randomized global study designed to assess the efficacy, safety, and tolerability of cipaglu...

ubs-maintains-buy-on-amicus-therapeutics-raises-price-target-to-22
UBS Maintains Buy on Amicus Therapeutics, ...
05/02/2025 22:37:55

UBS analyst Karl Chalabala maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and raises the price target from $21 to $22.

goldman-sachs-maintains-neutral-on-amicus-therapeutics-lowers-price-target-to-9
Goldman Sachs Maintains Neutral on Amicus ...
05/02/2025 16:47:03

Goldman Sachs analyst Salveen Richter maintains Amicus Therapeutics (NASDAQ:FOLD) with a Neutral and lowers the price target...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/01/2025 12:05:58

amicus-therapeutics-sees-fy25-revenue-growth-of-17---24
Amicus Therapeutics Sees FY25 Revenue Grow...
05/01/2025 11:11:34

amicus-therapeutics-q1-adj-eps-003-beats-005-estimate-sales-12520m-miss-13586m-estimate
Amicus Therapeutics Q1 Adj. EPS $0.03 Beat...
05/01/2025 11:10:22

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $...

Core News & Articles
Earnings Scheduled For May 1, 2025
05/01/2025 08:32:37

reported-earlier-dimerix-and-amicus-therapeutics-sign-exclusive-us-license-agreement-for-dmx-200-in-fsgs-treatment
Reported Earlier, Dimerix And Amicus Thera...
05/01/2025 07:19:37

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) D...

amicus-therapeutics-earnings-preview
Amicus Therapeutics Earnings Preview
04/30/2025 16:01:30

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION